Dupilumab was approved for the treatment of moderate to severe atopic dermatitis (AD) in 2018. This study evaluated the effect of 16 weeks treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate‐severe AD.
Effectiveness of dupilumab was expressed as number of patients achieving EASI‐50 (Eczema Area and Severity Index) or EASI‐75, as well as patient reported outcomes measures (Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus).
138 patients were treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult‐to‐treat AD -- 60% of them patients did not improve on 2 or more immunosuppressive drugs.
After 4 months, at week 16, the mean percent change in EASI score was 73%.
The most reported side effect was conjunctivitis, occurring in 34% patients. This is way higher than the reported incidence of 11-13% in the drug brochure.
During dupilumab treatment, disease severity related serum biomarkers (TARC, PARC, periostin, and IL‐22), eotaxin‐1, and eotaxin‐3 significantly decreased.
Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Lieneke FM Ariëns et al.